News Daily News Big Downturn in CVD Procedures Seen During COVID-19’s First Wave Michael O'Riordan July 01, 2021
News Conference News ACC 2021 Extended TAILOR-PCI Data Again Show No Gains for Genotype-Guided Meds Yael L. Maxwell May 26, 2021
News Conference News EuroPCR 2021 FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold Michael O'Riordan May 19, 2021
News Conference News EuroPCR 2021 Elective Revascularization, Better Long-term Survival: Meta-analysis Michael O'Riordan May 18, 2021
News Conference News ACC 2021 Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’ Michael O'Riordan May 18, 2021
News Conference News ACC 2021 Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC Michael O'Riordan May 17, 2021
News Conference News ACC 2021 Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT Yael L. Maxwell May 15, 2021
News Conference News SCAI 2021 ISCHEMIA: PCI/CABG Has Early Hospitalization ‘Tax’ but Equals Meds Later Michael O'Riordan May 06, 2021
News Conference News ACC 2021 Poorer Neighborhoods Pose Risks for Black Patients After Acute MI L.A. McKeown May 05, 2021
News Conference News SCAI 2021 In African-American Patients, Nontraditional Risk Factors Track With Early CAD Michael O'Riordan April 28, 2021
News Daily News In Female Veterans With Early ASCVD, Secondary Prevention Falls Short Michael O'Riordan April 21, 2021
News Daily News Dual Bests Triple Therapy in Nonvalvular AF Patients in RE-DUAL PCI Yael L. Maxwell April 09, 2021
News Daily News ‘Gaming’ the AUC for Revascularization? Study Suggests Not Michael O'Riordan March 25, 2021
News Daily News Meta-analysis Supports Genotype-Guided P2Y12 Prescription for ACS Yael L. Maxwell March 25, 2021
News Daily News MI Hospitalizations Down 20% at COVID-19 Peak in Italy, With a Heavy Cost Michael O'Riordan March 04, 2021
News Daily News EVOLVE Short DAPT in Print: P2Y12 Decisions Can Safely Be Made Case-by-Case Yael L. Maxwell March 03, 2021
News Daily News Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval Michael O'Riordan March 03, 2021